What exactly is the new crown vaccine called cost pricing?! "

Old Xue Xinguan vaccine door, the rich do not enter! According to a recent press conference of the State Council, China's new crown vaccine annual production capacity can reach 610 million doses, and will be based on cost pricing.
: China News Network public number screenshot this is priced at cost, side description of what? First, the regulatory authorities will be related to the cost of vaccines do not account for, it is not possible to determine the cost.
Of course, this cost accounting, will never be like the collection of the amount of the way to see the direct conversion of raw materials, will take into account research and development costs, equipment wear and tear, labor and other factors.
so there will not be a collection of "your medicine sold more than a hair, is someone else's home 119 times" paragraph, clearly their own enterprise's research and development costs directly related to the final price.
this sensitive period, if in order to set high prices for products, and deliberately exaggerate costs, then the corresponding punishment and public opinion pressure is bound to be very heavy.
. Despite the high demand for new crown vaccines, many new drugs with low pricing authority are in the early stages of market, on the one hand, patent protection, on the other hand, based on fewer competitors, there will be a relatively broad autonomy to price.
is also the industry for the research and development process of a certainty, many drugs in the initial stage and a few years after the market, there are very large price changes.
, with the exception of the new crown vaccine, which is self-purchased, companies lose pricing power, which means limited profits.
's this happening? First, the medical insurance funding factors we all know that the current drug collection and collection of the original intention is to save the health insurance fund.
In other words, health care money is not enough if you don't squeeze out water, and if you allocate a lot of that limited amount of money (even if you think only of the big city people, it must be a lot), then normal health care will be limited."
, either from other parts of medicare or from personal consumption.
if it is personal consumption, in order to increase popularity, must be the bottom price plus low profit model.
, epidemic prevention and control as a disease that can be transmitted from object contact, but also respiratory tract and other channels, all people who go out to activities, socializing is necessary to prevent.
with the exception of some sectors, where free injections are available, most people pay for them on their own.
also said that this belongs to the third phase of clinical category, should be enterprise funding.
don't forget one thing: Phase III clinical trials and unlisted emergency use are different categories and different concepts.
price reduction, it can increase the motivation of low-income people to actively immunized.
does this affect the new crown vaccine companies? First, stocks may fluctuate many companies' love for the new crown vaccine, from two parts, one is epidemic prevention;
so every time a listed company announces a vaccine into clinical practice, it sets off a rally.
even some enterprises to wipe the edge ball, but also to rub this heat.
, but now that vaccines mean low profits, will capital continue to chase? As some analysts abroad have pointed out, if the vaccine is effective and on the market, then the unified procurement of the country, with the power of one country plus public opinion, will certainly make the profit very low.
, whether the vaccine succeeds or not, it doesn't make a huge profit for businesses.
now that the authorities have constrained prices, stocks that had been on fire in the early stages could fluctuate or even fall sharply.
, did not reach the clinical stage three or is in the clinical stage three may be stranded although none of them are listed, but the number of research and development institutions is very large.
an analyst once used the term "saturation research and development" when it comes to vaccine research and development.
do you mean? That is, in addition to many enterprises, the technical route is also a stream of contention.
from inactivated vaccines, recombined protein vaccines to RNA vaccines, viral vector vaccines, bacterial vector vaccines, only you can't imagine, not try.
even appeared a law, when the new crown vaccine of A enterprises burst into negative news, then not only will affect the fall of A enterprises' stocks, but also affect the use of the same technology route of B enterprises, C enterprises---。
after all, in the early stage, government agencies did not make price constraints, so on the one hand, for stocks and reflect their own ability, on the other hand, but also for profit, came.
now pricing at cost, directly out of the way of some people, so it is very likely that some enterprises choose to exit.
timely stop loss is also a kind of hedging.
, of course, a drug market can make a profit, but often it does more than that.
show their hand in the face of capital, even if there is no money, or even lose money, stocks may appreciate, at least there is hope for financing.
this is an example in the history of medicine, in 1996 Gilead a new drug came on the market, but underperformed, annual sales never exceeded $10 million, even research and development costs have not been recovered.
the success of the new drug, which raised nearly $250 million, also has the story of the drug industry star behind it.
so "complaining too much to prevent intestinal breaks, wind long should look at the amount", if the relevant enterprises have the ability to continue, or to come up with the courage to go well behind this chess.
don't give up because the new crown vaccine does not make money in the short term, once really leave the scene, "even if there are a thousand customs, but also with who to say?" "